Phase 1 Study of Zanubrutinib Plus Lenalidomide in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma - PubMed
7 hours ago
- #Lenalidomide
- #DLBCL
- #Zanubrutinib
- Phase 1 study evaluated zanubrutinib plus lenalidomide in relapsed/refractory DLBCL patients.
- Zanubrutinib is a next-generation BTK inhibitor with high selectivity.
- Lenalidomide RP2D was 25 mg once daily combined with zanubrutinib 160 mg twice daily.
- Common grade ≥3 TEAEs included decreased neutrophil count (58%) and WBC count (29%).
- ORR was 58% with a complete response rate of 42% at RP2D.
- Median duration of response was 14.9 months; median PFS was 5.5 months.
- Combination therapy showed acceptable tolerability and antitumor activity in R/R DLBCL.